Cabozantinib (Cometriq®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000589
English
Authors' recommendations:
Cabozantinib (Cometriq®) is recommended as an option for use within NHS Wales for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/577
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Thyroid Neoplasms
- Anilides
- Pyridines
- Antineoplastic Agents
- Protein Kinase Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.